Actively Recruiting
Tracking Outcomes of Chronic Epstein-Barr Virus Infection in Healthy Volunteers with High EBV DNA Levels
Led by Huazhong University of Science and Technology · Updated on 2021-02-10
10000
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying people who have a high amount of Epstein-Barr virus DNA in their blood but have healthy immune systems. The goal is to understand how this chronic high level of the virus might relate to blood cancers and to explore the genetic reasons why the virus can evade the immune system and potentially lead to tumors. This study focuses on the natural history of long-term latent EBV infection and its possible connection to serious blood diseases. Participants with a high EBV-DNA load in their blood are enrolled and followed over time without any treatment intervention. They are grouped based on their viral load into mild high load and severe high load categories. Follow-up occurs through regular phone calls or face-to-face interviews to monitor their health and any development of blood-related cancers, such as lymphomas and other EBV-associated diseases. During the study, participants undergo periodic assessments to track their condition, including monitoring for hematological malignancies over five years or longer if needed. Researchers collect data through interviews and clinical examinations to understand disease progression and genetic factors involved. The study aims to provide insights into how chronic EBV infection may lead to cancer and immune system escape, with ongoing monitoring to ensure participant safety and data accuracy.
CONDITIONS
Brief Title
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Research Team
J
Jin Huang, PhD.and MD.
J
Jianfeng Zhou, PhD.and MD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here